title: Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria.
abstract: OBJECTIVE
  To investigate the correlation between in vitro and in vivo immunomodulation potential of the probiotic strain and its ability to prevent experimental colitis in mice.
  
  
  METHODS
  In vitro immunomodulation was assessed by measuring interleukin (IL)-12p70, IL-10, tumor necrosis factor alpha (TNFalpha) and interferon gamma (IFNgamma) release by human peripheral blood mononuclear cells (PBMCs) after 24 h stimulation with 13 live bacterial strains. A murine model of acute TNBS-colitis was next used to evaluate the prophylactic protective capacity of the same set of strains.
  
  
  RESULTS
  A strain-specific in vivo protection was observed. The strains displaying an in vitro potential to induce higher levels of the anti-inflammatory cytokine IL-10 and lower levels of the inflammatory cytokine IL-12, offered the best protection in the in vivo colitis model. In contrast, strains leading to a low IL-10/IL-12 cytokine ratio could not significantly attenuate colitis symptoms.
  
  
  CONCLUSIONS
  These results show that we could predict the in vivo protective capacity of the studied lactic acid bacteria (LAB) based on the cytokine profile we established in vitro. The PBMC-based assay we used may thus serve as a useful primary indicator to narrow down the number of candidate strains to be tested in murine models for their anti-inflammatory potential.
authors.affiliation: Bactéries Lactiques and Immunité des Muqueuses, Institut Pasteur de Lille, 1 Rue du Professeur Calmette, Lille cedex F-59019, France.
authors.forename: Benoit
authors.initials: B
authors.lastname: Foligne
authors.forename: Sophie
authors.initials: S
authors.lastname: Nutten
authors.forename: Corinne
authors.initials: C
authors.lastname: Grangette
authors.forename: Véronique
authors.initials: V
authors.lastname: Dennin
authors.forename: Denise
authors.initials: D
authors.lastname: Goudercourt
authors.forename: Sabine
authors.initials: S
authors.lastname: Poiret
authors.forename: Joelle
authors.initials: J
authors.lastname: Dewulf
authors.forename: Dominique
authors.initials: D
authors.lastname: Brassart
authors.forename: Annick
authors.initials: A
authors.lastname: Mercenier
authors.forename: Bruno
authors.initials: B
authors.lastname: Pot
mesh_terms: D000818:Animals; D003092:Colitis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D003106:Colon / Q000473:pathology; D016207:Cytokines / Q000032:analysis; D004195:Disease Models, Animal; D006801:Humans; D007778:Lactobacillus / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000494:pharmacology / Q000627:therapeutic use*; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
chemical_list: D016207:Cytokines; D014302:Trinitrobenzenesulfonic Acid